Clinical Trial Update: Erlotinib Study for Myelodysplastic Syndrome (MDS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Erlotinib for Myelodysplastic Syndrome has completed; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2013-09-16